Frontier Medicines Stock

frontiermeds.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $255.5MM

Frontier Medicines is a precision medicine company that develops breakthrough medicines for patients. Specifically, the company focuses on developing therapies for previously undruggable disease-causing proteins. Through its proprietary Frontier Platform, the company combines scientific approaches that include chemoproteomics, covalent drug discovery, and machine learning. Frontier Medicines was founded in 2018 by Chris Varma Ph.D and headquartered in San Francisco, CA.

Register To Buy and Sell Shares

For more details on financing and valuation for Frontier Medicines, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Frontier Medicines’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Frontier Medicines.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Chris Varma Ph.D
Co-Founder, Chief Executive Officer & President
Roberto Zoncu Ph.D
Co-Founder & Advisor
Daniel Nomura Ph.D
Co-Founder & Advisor
Johannes Hermann Ph.D
Chief Technology Officer
Monique Bobadilla
Chief People and Culture Officer
Kevin Webster Ph.D
Chief Scientific Officer
Andrew Krivoshik MD
Chief Medical Officer
Gregory Chow
Chief Financial Officer

Board Members

Cameron Wheeler Ph.D
Deerfield Management
Derek DiRocco Ph.D
RA Capital Management
Luke Evnin Ph.D
MPM BioImpact

Frequently Asked Questions About Frontier Medicines’ Stock

plusminus
Can you buy Frontier Medicines’ stock?
Frontier Medicines is not publicly traded on NYSE or NASDAQ in the U.S. To buy Frontier Medicines’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Frontier Medicines’ stock?
Yes, you can sell stock of a private company like Frontier Medicines. Forge can help you sell your Frontier Medicines stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Frontier Medicines’ stock price?
Frontier Medicines is a privately held company and therefore does not have a public stock price. However, you may access Frontier Medicines’ private market stock price with Forge Data.
plusminus
What is Frontier Medicines’ stock ticker symbol?
Frontier Medicines does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Frontier Medicines Raises $80M in Series C, Targets Amgen and BMS in KRAS
Frontier Medicines on Thursday closed its oversubscribed $80 million Series C funding round, which it will use to advance its potentially first-in-class next-generation KRAS blocker FMC-376. The financing brings Frontier’s total capital raised to $235.5 million since its founding, according to the announcement. The funding round was co-led by Deerfield Management Company and Droia Ventures. Galapagos NV, a Belgium-based pharmaceutical company, participated as a strategic investor, along with contributions from MPM Capital, RA Capital Management and DCVC Bio.
Updated on: Apr 14, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.